[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581762":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":42,"locations":48,"responsibleParty":73,"collaborators":28,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":28,"enrollmentInfo":87,"targetDuration":28,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":28,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"PCSK9 inhibitor group","EXPERIMENTAL","In this group, patients will receive PCSK9 inhibitor treatment",[13,14],"Drug: PCSK9 inhibitor","Behavioral: Blood lipid levels meet the recommended guidelines",{"label":16,"type":17,"description":18,"interventionNames":19},"Statin+ezetimibe group","ACTIVE_COMPARATOR","In this group, patients will receive statin and ezetimibe treatment",[20,21],"Drug: Statin+ezetimibe","Behavioral: Blood lipid levels don't meet the recommended guidelines",[23,29,33,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","PCSK9 inhibitor","The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Statin+ezetimibe","The patient used statins and ezetimibe within 24 hours before or after PCI, and then once a day for 12 months",[16],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"BEHAVIORAL","Blood lipid levels meet the recommended guidelines","Early use of intensified lipid-lowering therapy during hospitalization led to a rapid decrease in blood lipids and met the recommended guidelines.",[9],{"type":34,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Blood lipid levels don't meet the recommended guidelines","The patient did not receive intensified lipid-lowering treatment during hospitalization or did not meet the recommended guidelines for blood lipids",[16],[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Dandan Li","CONTACT","8613810545564","lidandan5564@163.com",[49,66],{"facility":5,"status":28,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Beijing","Beijing Municipality","100853","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.39723,39.9075,{"lat":59,"lon":58},[62],{"name":63,"role":45,"phone":64,"phoneExt":65,"email":47},"Dandan Li, MD","13810545564","86",{"facility":67,"status":28,"city":50,"state":28,"zip":28,"country":53,"countryCode":54,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Chinese PLA General Hospital [",{"type":56,"coordinates":69},[58,59],{"lat":59,"lon":58},[72],{"name":44,"role":45,"phone":64,"phoneExt":28,"email":47},{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Yun Dai Chen","professor","100581762","assessing-coronary-non-culprit-plaque-early-with-start-of-pcsk9-inhibitors-in-acute-myocardial-infarction-access-ami-100581762",false,"NCT06854523","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)","Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction","ACCESS-AMI","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Admitted to hospital for acute myocardial infarction (STEMI, NSTEMI) and successfully underwent PCI of the infarct vessel.\n3. Coronary angiography revealed two non-infarct-related arteries with non-blocking lesions (diameter stenosis of 40-70%).\n4. Able to sign informed consent.\n5. Willing to undergo 1-year follow-up.\n\nExclusion Criteria:\n\n1. Left main artery disease or severe coronary artery calcification;\n2. Hemodynamic instability or uncontrolled arrhythmia;\n3. History of coronary artery bypass;\n4. severe renal insufficiency, active liver disease or liver insufficiency, hematological disease, metabolic or endocrine dysfunction, systemic infection, active malignant tumor and other potentially life-threatening diseases, or the expected survival time is \\\u003C 1 year;\n5. Received any PCSK9 inhibitor treatment within the previous 3 months;\n6. Pregnant or nursing women or women planning pregnancy;\n7. The researcher determined that it was not suitable for inclusion in the group.","ALL","18 Years",{"count":88,"type":89},300,"ESTIMATED","INTERVENTIONAL",[92],"NA","This study is planned to start on January 2024.\n\nThe goal of this clinical trial is to learn whether the perioperative administration (within 24 hours before or after primary PCI) of PCSK9 inhibitors can ameliorate plaque progression and adverse outcomes in patients with acute myocardial infarction (AMI). The main questions it aims to answer are:\n\nCan perioperative PCSK9 inhibition improve the plaque stability and inflammation of perivascular adipose tissue (index of plaque attenuation（IPA ）and perivascular fat attenuation index（FAI）) of non-target lesions? Researchers will compare PCSK9 inhibitors with statin plus ezetimibe therapy to evaluate the potential of PCSK9 inhibitors in mitigating the progression of non-target lesion plaques and reducing adverse cardiovascular events in patients with AMI.\n\nParticipants will:\n\nTake PCSK9 inhibitors every two weeks or daily statin plus ezetimibe therapy. Conduct a follow-up examination with optical coherence tomography (OCT) or coronary computed tomography angiography (CTA) after 12 months.\n\nRecord the occurrence of major adverse cardiovascular events.",[95],"Acute Myocardial Infarction",[95,97,98,99],"Pericoronary artery fat attenuation index","Index of Plaque Attenuation","PCSK9 Inhibitor","NOT_YET_RECRUITING","2025-02-25",{"date":103,"type":104},"2025-03-03","ACTUAL",{"date":106,"type":89},"2025-04-15",{"date":108,"type":89},"2026-12-31",{"name":75,"class":6},2]